EyePoint (EYPT) Enterprise Value (2010 - 2026)
EyePoint (EYPT) posted Enterprise Value of -$222.5 million for Q1 2026, up 27.29% sequentially from -$306.1 million in Q4 2025, and up 30.06% YoY from -$171.1 million in Q1 2025.
EyePoint (EYPT) Enterprise Value (2010 - 2026) Analysis & Trends
EyePoint has reported Enterprise Value for 17 years, with the latest figure at -$222.5 million in Q1 2026.
- Quarterly Enterprise Value rose 30.06% year-over-year to -$222.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$222.5 million (up 30.06% YoY) and the FY2025 annual result came in at -$306.1 million, up 17.48% from the prior year.
- Enterprise Value rose to -$222.5 million in Q1 2026 per EYPT's latest filing, from -$306.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$122.5 million in Q1 2023 and troughed at -$370.9 million in Q4 2024.
- A 5-year average of -$229.8 million and a median of -$222.5 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 35.81% in 2023, then sank 144.44% in 2024.
- Over 5 years, Enterprise Value stood at -$144.6 million in 2022, then tumbled by 129.0% to -$331.0 million in 2023, then decreased by 12.04% to -$370.9 million in 2024, then advanced by 17.48% to -$306.1 million in 2025, then grew by 27.29% to -$222.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$222.5 million, -$306.1 million, and -$204.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -180.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -180.47 Mn |
| Mar 31, 2026 | -222.55 Mn |
| Dec 31, 2025 | -306.09 Mn |
| Sep 30, 2025 | -204.02 Mn |
| Jun 30, 2025 | -255.73 Mn |
| Mar 31, 2025 | -318.19 Mn |
| Dec 31, 2024 | -370.91 Mn |
| Sep 30, 2024 | -253.79 Mn |
| Jun 30, 2024 | -280.25 Mn |
| Mar 31, 2024 | -299.35 Mn |
| Dec 31, 2023 | -331.05 Mn |
| Sep 30, 2023 | -136.01 Mn |
| Jun 30, 2023 | -142.50 Mn |
| Mar 31, 2023 | -122.47 Mn |
| Dec 31, 2022 | -144.56 Mn |
| Sep 30, 2022 | -157.26 Mn |
| Jun 30, 2022 | -171.17 Mn |
| Mar 31, 2022 | -190.78 Mn |
| Dec 31, 2021 | -211.56 Mn |
| Sep 30, 2021 | -119.71 Mn |